Linezolid Resistance in Methicillin-Resistant Staphylococcus aureus in Korea: High Rate of False Resistance to Linezolid by the VITEK 2 System
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
As various linezolid resistance mechanisms have been identified in methicillin-resistant Staphylococcus aureus (MRSA), we investigated the molecular characteristics of MRSA with elevated linezolid minimum inhibitory concentrations (MICs), using the VITEK 2 system (bioMérieux, Marcy-l’Étoile, France). Twenty-seven MRSA isolates from 14 patients exhibiting linezolid MICs ≥8 μg/mL were examined by broth microdilution (BMD) test as well as by sequencing for mutations in the 23S rRNA gene or ribosomal proteins (L3, L4, and L22) and the presence of the optrA, cfr, and cfr(B) genes. Of the 27 isolates, four (14.8%) from one patient were confirmed as linezolid resistant by BMD and harbored a 23S rRNA T2500A mutation. The remaining 23 were confirmed as linezolid susceptible, indicating that the linezolid-resistant results were major errors generated by VITEK 2. The most commonly detected mutation (19/27, 70.4%), L3 Gly152Asp, was detected in only linezolid-susceptible isolates. No isolates contained optrA, cfr, or cfr(B) or any L4 or L22 protein alterations. Our results show that the 23S rRNA T2500A mutation was mainly associated with linezolid resistance, while the L3 Gly152Asp mutation was not related to linezolid resistance. A confirmatory test is recommended for VITEK 2 linezolid-resistant results owing to the high probability of false resistant results.
Abstract
As various linezolid resistance mechanisms have been identified in methicillin-resistant Staphylococcus aureus (MRSA), we investigated the molecular characteristics of MRSA with elevated linezolid minimum inhibitory concentrations (MICs), using the VITEK 2 system (bioMérieux, Marcy-l’Étoile, France). Twenty-seven MRSA isolates from 14 patients exhibiting linezolid MICs ≥8 μg/mL were examined by broth microdilution (BMD) test as well as by sequencing for mutations in the 23S rRNA gene or ribosomal proteins (L3, L4, and L22) and the presence of the optrA, cfr, and cfr(B) genes. Of the 27 isolates, four (14.8%) from one patient were confirmed as linezolid resistant by BMD and harbored a 23S rRNA T2500A mutation. The remaining 23 were confirmed as linezolid susceptible, indicating that the linezolid-resistant results were major errors generated by VITEK 2. The most commonly detected mutation (19/27, 70.4%), L3 Gly152Asp, was detected in only linezolid-susceptible isolates. No isolates contained optrA, cfr, or cfr(B) or any L4 or L22 protein alterations. Our results show that the 23S rRNA T2500A mutation was mainly associated with linezolid resistance, while the L3 Gly152Asp mutation was not related to linezolid resistance. A confirmatory test is recommended for VITEK 2 linezolid-resistant results owing to the high probability of false resistant results.
참고문헌 (16)
- Wilson P, "Linezolid resistance in clinical isolates of Staphylococcus aureus", J Antimicrob Chemother, 51, pp.186~188 (2003)
- Meka VG, "Linezolid resistance in sequential Staphylococcus aureus isolates associated with a T2500A mutation in the 23S rRNA gene and loss of a single copy of rRNA", J Infect Dis, 190, pp.311~317 (2004)
- Long KS, "Resistance to linezolid caused by modifications at its binding site on the ribosome", Antimicrob Agents Chemother, 56, pp.603~612 (2012)
- Hill RL, "Linezolid-resistant ST36 methicillin-resistant Staphylococcus aureus associated with prolonged linezolid treatment in two paediatric cystic fibrosis patients", J Antimicrob Chemother, 65, pp.442~445 (2010)
- Locke JB, "Novel ribosomal mutations in Staphylococcus aureus strains identified through selection with the oxazolidinones linezolid and torezolid (TR-700)", Antimicrob Agents Chemother, 53, pp.5265~5274 (2009)
- Locke JB, "Linezolid-resistant Staphylococcus aureus strain 1128105, the first known clinical isolate possessing the cfr multidrug resistance gene", Antimicrob Agents Chemother, 58, pp.6592~6598 (2014)
- Antonelli A, "Linezolid-resistant cfr-positive MRSA, Italy", J Antimicrob Chemother, 71, pp.2349~2351 (2016)
- Lee SM, "Resistance mechanisms of linezolid-nonsusceptible enterococci in Korea : low rate of 23S rRNA mutations in Enterococcus faecium", J Med Microbiol, 66, pp.1730~1735 (2017)
- CLSI, "Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically" (2018), Clinical and Laboratory Standards Institute
- CLSI, "Performance standards for antimicrobial susceptibility testing" (2018), Clinical and Laboratory Standards Institute
- Mendes RE, "ZAAPS programme results for 2016 : an activity and spectrum analysis of linezolid using clinical isolates from medical centres in 42 countries", J Antimicrob Chemother, 73, pp.1880~1887 (2018)
- Flamm RK, "Linezolid surveillance results for the United States(LEADER surveillance Program 2014)", Antimicrob Agents Chemother, 60, pp.2273~2280 (2016)
- Tsiodras S, "Linezolid resistance in a clinical isolate of aureus", Lancet, 358, pp.207~208 (2001)
- Baos E, "of Staphylococcus epidermidis in an intensive care unit 4 years after an outbreak of infection by cfr-mediated linezolid-resistant Staphylococcus aureus", Diagn Microbiol Infect Dis, 76, pp.325~329 (2013)
- Doern CD, "Investigation of linezolid resistance in staphylococci and enterococci", J Clin Microbiol, 54, pp.1289~1294 (2016)
- Tenover FC, "Accuracy of six antimicrobial susceptibility methods for testing linezolid against staphylococci and enterococci", J Clin Microbiol, 45, pp.2917~2922 (2007)